Compare GYRE & LEGH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GYRE | LEGH |
|---|---|---|
| Founded | 2002 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Homebuilding |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 624.9M | 528.7M |
| IPO Year | 2004 | 2018 |
| Metric | GYRE | LEGH |
|---|---|---|
| Price | $6.08 | $22.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $17.00 | ★ $25.00 |
| AVG Volume (30 Days) | 66.5K | ★ 67.7K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.46 |
| Revenue | $275,000.00 | ★ $164,567,000.00 |
| Revenue This Year | $19.88 | $11.90 |
| Revenue Next Year | N/A | $6.58 |
| P/E Ratio | ★ N/A | $49.80 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.97 | $18.29 |
| 52 Week High | $11.61 | $29.45 |
| Indicator | GYRE | LEGH |
|---|---|---|
| Relative Strength Index (RSI) | 32.71 | 58.79 |
| Support Level | N/A | $20.53 |
| Resistance Level | $8.26 | $24.00 |
| Average True Range (ATR) | 0.38 | 0.94 |
| MACD | -0.15 | 0.06 |
| Stochastic Oscillator | 4.01 | 76.49 |
Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.
Legacy Housing Corp builds, sells, and finances manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores, and are also sold directly to manufactured home communities. The Company manufactures and provides for the transport of manufactured homes, provides wholesale financing to dealers and mobile home parks, provides retail financing to consumers, and is involved in financing and developing new manufactured home communities. The Company manufactures its mobile homes at plants in Fort Worth, Texas; Commerce, Texas; and Eatonton, Georgia. The Company also sells homes directly to consumers, through its own retail stores, and to dealers and mobile home parks.